ArticlePleura and peritoneum2026
The utility of a pleural carcinomatosis score for assessing resectability.
Article in Pleura and peritoneum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Malignant pleural effusion is a common evolution of various cancers and is associated with poor prognosis and quality of life. Currently, the surgical approach is mainly palliative, involving videothoracoscopic talc pleurodesis or the insertion of indwelling pleural catheters. No surgical options with a curative intent are validated for this indication. The aim of our study was to evaluate a score for assessing resectability in pleural carcinomatosis. Methods: 122 consecutive patients with recurrent symptomatic pleural effusion, referred to our thoracic surgery department for a surgical exploration of the pleura, were prospectively included. Each patient underwent a detailed description of videothoracoscopic findings, which were summarized in our pleural carcinomatosis score. Resectability was then discussed in our surgical staff meeting. Results: Eighty patients (65.6 %) were diagnosed with metastatic pleural spread, while 42 patients were diagnosed with benign pleural disease (34.4 %). Patients diagnosed with benign pleural effusion had a median score of 2, and 29 patients (69 %) were considered resectable. Patients diagnosed with malignant pleural effusion had a median score of 11, and only 13 patients (16.2 %) were considered resectable. Those deemed resectable had a median score of 5. The threshold for resectability in our score was set at 6. Conclusions: The meticulous exploration of the pleura and calculation of the pleural carcinomatosis score could aid in selecting patients for curative-intent surgery. Patients with a score equal to or less than 6 should be discussed in a multidisciplinary tumor board where the possibility of surgery is considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.